31-Jul-2026
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
Globe Newswire (Fri, 24-Jul 5:00 PM ET)
Market Chameleon (Mon, 29-Jun 7:43 AM ET)
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
Globe Newswire (Mon, 29-Jun 7:00 AM ET)
Globe Newswire (Tue, 16-Jun 7:00 AM ET)
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Thu, 28-May 7:00 AM ET)
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Globe Newswire (Tue, 12-May 7:00 AM ET)
Market Chameleon (Tue, 6-Jan 4:55 AM ET)
Market Chameleon (Tue, 6-Jan 4:21 AM ET)
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Novabridge Biosciences - American Depositary Shares trades on the NASDAQ stock market under the symbol NBP.
As of July 31, 2026, NBP stock price declined to $1.60 with 166,080 million shares trading.
NBP has a beta of 0.97, meaning it tends to be less sensitive to market movements. NBP has a correlation of 0.03 to the broad based SPY ETF.
NBP has a market cap of $184.43 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that NBP belongs to (by Net Assets): IBB, SPEM, SBIO, QQQS, EWX.
NBP support price is $1.56 and resistance is $1.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBP shares will trade within this expected range on the day.